June 20^th, 2017: Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round.

Jan 16^th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.

Jan 13^th, 2017: Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project.

Apr 7^th, 2016: First patient treated in MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.

Feb 26^th, 2016: Start of MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.

Dec 15^th, 2015: "Myelo Therapeutics Receives Approval to Start Phase II of Myelo001 in Chemotherapy-induced Neutropenia and Closes Series B Financing Round".

June 27^th, 2015: "Myelo001 – A Novel Small Molecule for the Treatment of Chemotherapy-Induced Myelosuppression" was presented at the MASCC/ISOO 2015 Annual Meeting on Supportive Care in Cancer.

Oct 6^th, 2014: "Effect of Myelo001, a Novel Orally Bioavailable Small Molecule, on Chemotherapy-induced Myelosuppression" was accepted for poster presentation and publication at the 56th meeting of the American Society of Hematology, on Monday, Dec 8th, 2014 from 6:00 – 8:00pm.

Sept 12^th, 2014: Myelo Therapeutics has been selected to present at Falling Walls Venture on Nov 8th, 2014 in Berlin:
Falling Walls, the International Conference on Future Breakthroughs in Science and Society